Protinal C.A. (CCSE:PTN)

Revance Therapeutics Revenue

Protinal C.A. had revenue of 12.76M VEF in the quarter ending May 31, 2013, a decrease of -226.79%. This brings the company's revenue in the last twelve months to -56.77M, up 30.00% year-over-year. In the fiscal year ending August 31, 2012, Protinal C.A. had annual revenue of -38.58M with 14.20% growth.

• Revenue (ttm): -56.77M VEF
• Revenue Growth: +30.00%
• P/S Ratio: -28.02
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 1.59B USD

Revenue Chart

* This company reports financials in VEF.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Aug 31, 2012	-38.58M	-4.80M	14.20%
Aug 31, 2011	-33.78M	-61.57M	-221.57%
Aug 31, 2010	27.79M	37.03M	-400.89%
Aug 31, 2009	-9.24M	-12.60M	-374.71%
Aug 31, 2008	3.36M	-23.44M	-87.46%